# ADEL, Inc.

**Canonical:** https://apis.io/providers/adel97fd/  
**Website:** https://adelpharm.com/en/  
**APIs profiled:** 0

ADEL, Inc. (주식회사 아델) is a clinical-stage biopharmaceutical company headquartered in Seoul, South Korea, founded in 2016 as a spin-off from the Asan Medical Center / University of Ulsan College of Medicine by Professor Seung-Yong Yoon. ADEL develops antibody therapeutics, companion diagnostics and delivery platforms for Alzheimer's disease and other neurodegenerative conditions. Its lead candidate ADEL-Y01 is a humanized monoclonal antibody selectively targeting tau acetylated at Lysine-280 (acK280), in a global first-in-human Phase 1 study under a US FDA-cleared IND; in December 2025 ADEL granted Sanofi exclusive worldwide rights to ADEL-Y01 in a deal worth up to USD 1.04 billion including an USD 80 million upfront payment. The wider pipeline includes ADEL-Y03 (a beta-2 microglobulin antibody), ADEL-Y04 (an ApoE4-targeting antibody), the ADEL-D01 tau pT217 diagnostic antibody, and two proprietary platforms — BTS (Brain Targeting System) for blood-brain-barrier penetration and ADTAC (Autophagic Degradation Targeting Chimera) for targeted protein degradation. The company is research-and-development driven and sells no software product: it publishes no developer portal, public API, SDK, webhook catalog or machine-readable specification of any kind. Its only web surface is the corporate marketing site at adelpharm.com.

## Kin Score — 2.9 / 100 (minimal)

Scored 2026-09-07 under rubric 0.20.0.

| Facet | Score |
|---|---|
| Discoverability | 46.3 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 2.9 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | yes |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (1)

- **Adel97Fd Domain Security** — TLSv1.2

## Tags

Company, Biotechnology, Pharmaceuticals, Life Sciences, Healthcare, Drug Discovery, Antibody Therapeutics, Neuroscience, Alzheimers Disease, Clinical Trials, Diagnostics, South Korea

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/adel97fd/). Scores are computed from the provider's own public artifacts under a published rubric.